DR. LAUREN AVERETT BYERS, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas M5082
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about LAUREN AVERETT BYERS at radaris.comName
Address
Phone
1630 Rick Rhodes Dr #B, El Paso, TX 79936
200 Brazoswood Dr, Clute, TX 77531
31 E Burberry Cir, Conroe, TX 77384
3511 Amherst St, Houston, TX 77005
Professional information
See more information about LAUREN AVERETT BYERS at trustoria.com
Dr. Lauren A Byers - MD (Doctor of Medicine)
Dr. Lauren A Byers - MD (Doctor of Medicine)
Age:
49
Hospitals:
1515 Holcombe Blvd SUITE 10, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
1515 Holcombe Blvd SUITE 10, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
1515 Holcombe Blvd SUITE 10, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
Education:
Medical Schools
Baylor College of Medicine
Baylor College of Medicine
Lauren Averett Byers, Houston TX
Lauren Averett Byers, Houston TX
Specialties:
General Practice, Internal Medicine, Medical Oncology
Work:
M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
Baylor College of Medicine (2003)
Lauren Averett Byers, Houston TX
Lauren Averett Byers, Houston TX
Specialties:
Internist
Address:
1515 Holcombe Blvd, Houston, TX 77030
Biomarkers For Response To Tyrosine Kinase Pathway Inhibitors In Cancer
Biomarkers For Response To Tyrosine Kinase Pathway Inhibitors In Cancer
US Patent:
2013023, Sep 5, 2013
Filed:
Feb 4, 2013
Appl. No.:
13/758728
Inventors:
Ignacio I. WISTUBA - Houston TX, US
Monique B. NILSSON - Sugar Land TX, US
Lauren A. BYERS - Houston TX, US
Ximing TANG - Houston TX, US
Fei YANG - Houston TX, US
Edward KIM - Houston TX, US
Anne S. TSAO - Houston TX, US
Scott M. LIPPMAN - Houston TX, US
Waun Ki HONG - Houston TX, US
Roy S. HERBST - Houston TX, US
Monique B. NILSSON - Sugar Land TX, US
Lauren A. BYERS - Houston TX, US
Ximing TANG - Houston TX, US
Fei YANG - Houston TX, US
Edward KIM - Houston TX, US
Anne S. TSAO - Houston TX, US
Scott M. LIPPMAN - Houston TX, US
Waun Ki HONG - Houston TX, US
Roy S. HERBST - Houston TX, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
G01N 33/74, A61K 39/395, A61K 31/506, A61K 31/4439, C12Q 1/68, A61K 31/4045
US Classification:
4241331, 435 723, 435 611, 514414, 51425218, 514338
Abstract:
Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and/or who have undergone adjuvant therapy are also provided herein.